



NEONATAL MEDICATION PROTOCOLS

PNEUMOCOCCAL CONJUGATE VACCINE, 13-VALENT (Prevenar) NCCU Clinical Guidelines
Created by: NCCU KEMH/PMH
Date for review: Jun 2014 Perth. Western Australia

DRUG:	PNEUMOCOCCAL CONJUGATE VACCINE, 13-VALENT (Prevenar)
PRESENTATION:	Pre-filled syringe: 0.5mL
ACTION & INDICATION:	Pneumococcal conjugate vaccine, 13-valent, for the active immunisation of infants against invasive disease, pneumonia and otitis media caused by <i>Streptococcus pneumoniae</i> .
DOSE:	0.5mL 1 st dose 2 months 2 nd dose 3 - 4 months 3 rd dose 5 - 6 months
ADMINISTRATION:	Intramuscular: As per NCCU policy DO NOT GIVE INTRAVENOUSLY OR INTRADERMALLY.
ADVERSE EFFECTS:	Swelling, erythema, soreness at injection site Fever
COMMENTS:	Shake well to obtain a homogenous white suspension. Do not use if not uniformly suspended, or discoloured. Do not mix with other vaccines in the same syringe. Other childhood vaccines may be given at the same time, but not at the same injection site. Do not give during febrile illness or acute infection
REFERENCES:	The Australian Immunisation Handbook 10 th Ed 2013 NH&MRC West Australian Vaccination Schedule August 2013
DATE:	October 2013